Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations

References

• Daudt H, van Mossel C, Dennis D, et al. Survivorship care plans: a work in progress. Curr Oncol 2014;21(3):e466
   PubMed Web of Science ®Google Scholar
• Puglisi F, Fontanella C, Numico G, et al. Follow-up of patients with early breast cancer: Is it time to rewrite the story? Crit Rev Oncol Hematol 2014;91(2):130-41
   PubMed Web of Science ®Google Scholar
• Kort JD, Eisenberg ML, Millheiser LS, Westphal LM. Fertility issues in cancer survivorship. CA Cancer J Clin 2014;64(2):118-34
   Google Scholar
• Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis. Crit Rev Oncol Hematol 2014;92(3):194-207
   PubMed Web of Science ®Google Scholar
• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53(24):2231-47
   PubMed Web of Science ®Google Scholar
• Thakur A, Witteles RM. Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. J Card Fail 2014;20(3):155-8
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003;97(11):2869-79
   PubMed Web of Science ®Google Scholar
• Colombo A, Cipolla C, Beggiato M, Cardinale D. Cardiac toxicity of anticancer agents. Curr Card Rep 2013;15(5):1-11
   Google Scholar
• Van Cutsem E, Hoff P, Blum J, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002;13(3):484-5
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Collazos J, Gallardo M, Hernando G. Angina pectoris following cisplatin, etoposide, and bleomycin in a patient with advanced testicular cancer. Ann Pharmacother 1995;29(2):138-9
   Google Scholar
• Reykdal S, Sham R, Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res 1995;19(2):141-4
   Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26(32):5204-12
   PubMed Web of Science ®Google Scholar
• Elice F, Jacoub J, Rickles FR, et al. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 2008;83(11):862-70
   PubMed Web of Science ®Google Scholar
• Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27(1):127-45
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Future Oncol 2014;10(12):1981-92
   PubMed Web of Science ®Google Scholar
• Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012;4:CD006243
   PubMed Web of Science ®Google Scholar
• Hequet O, Le Q, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22(10):1864-71
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109(22):2749-54
   PubMed Web of Science ®Google Scholar
• Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23(13):2900-2
   PubMed Web of Science ®Google Scholar
• Šimůnek T, Štěrba M, Popelová O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009;61(1):154-71
   PubMed Web of Science ®Google Scholar
• Keizer H, Pinedo H, Schuurhuis G, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990;47(2):219-31
   PubMed Web of Science ®Google Scholar
• Kwok JC, Richardson DR. Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol Pharmacol 2002;62(4):888-900
   PubMed Web of Science ®Google Scholar
• Minotti G, Ronchi R, Salvatorelli E, et al. Doxorubicin Irreversibly Inactivates Iron Regulatory Proteins 1 and 2 in Cardiomyocytes Evidence for Distinct Metabolic Pathways and Implications for Iron-mediated Cardiotoxicity of Antitumor Therapy. Cancer Res 2001;61(23):8422-8
   PubMed Web of Science ®Google Scholar
• Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 2008;28:197-213
   PubMed Web of Science ®Google Scholar
• Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3(6):430-40
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18(11):1639-42
   PubMed Web of Science ®Google Scholar
• Schimmel KJ, Richel DJ, Van den Brink RB, Guchelaar H-J. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30(2):181-91
   PubMed Web of Science ®Google Scholar
• Leone T, Kelly D. Transcriptional control of cardiac fuel metabolism and mitochondrial function. Cold Spring Harb Symp Quant Biol 2011;76:175-82
   PubMedGoogle Scholar
• Lu Z, Xu X, Hu X, et al. PGC-1α regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid Redox Signal 2010;13(7):1011-22
   Google Scholar
• Yan X, Morgan JP. Neuregulin1 as novel therapy for heart failure. Curr Pharm Des 2011;17(18):1808-17
   Google Scholar
• Lee K-F, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995;378(6555):394-8
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhou M. Neuregulin signaling and heart failure. Curr Heart Fail Rep 2010;7(1):42-7
   Google Scholar
• Pentassuglia L, Sawyer DB. The role of Neuregulin-1β/ErbB signaling in the heart. Experimen Cell Res 2009;315(4):627-37
   Google Scholar
• Muthuswamy SK, Li D, Lelievre S, et al. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001;3(9):785-92
   PubMed Web of Science ®Google Scholar
• Sawyer DB, Zuppinger C, Miller TA, et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbb2 potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002;105(13):1551-4
   PubMed Web of Science ®Google Scholar
• Crone SA, Zhao Y-Y, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8(5):459-65
   PubMed Web of Science ®Google Scholar
• Peng X, Guo X, Borkan SC, et al. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. J Biol Chem 2005;280(13):13148-52
   PubMed Web of Science ®Google Scholar
• Gu J, Tamura M, Pankov R, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999;146(2):389-404
   PubMed Web of Science ®Google Scholar
• Vadlamudi RK, Sahin AA, Adam L, et al.Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett 2003;543(1):76-80
   Google Scholar
• Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006;41(2):228-35
   PubMed Web of Science ®Google Scholar
• Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85(3):1093-29
   PubMed Web of Science ®Google Scholar
• Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Library 2014;6:CD006242
   PubMed Web of Science ®Google Scholar
• Walker J, Bhullar N, Fallah-Rad N, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010;28(21):3429-36
   PubMed Web of Science ®Google Scholar
• James MN, Sielecki AR. Stereochemical analysis of peptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. Biochemistry 1985;24(14):3701-13
   PubMed Web of Science ®Google Scholar
• Batenburg WW, Garrelds IM, Bernasconi CC, et al. Angiotensin II type 2 receptor–mediated vasodilation in human coronary microarteries. Circulation 2004;109(19):2296-301
   Google Scholar
• De Gasparo M, Catt K, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52(3):415-72
   PubMed Web of Science ®Google Scholar
• Paradis P, Dali-Youcef N, Paradis FW, et al. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci 2000;97(2):931-6
   Google Scholar
• Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010;122(7):717-28
   PubMed Web of Science ®Google Scholar
• Wang W, Bodiga S, Das SK, et al. Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev 2012;17(4-5):683-91
   Google Scholar
• Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1–7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998;31(1):356-61
   Google Scholar
• Lopaschuk GD, Ussher JR, Folmes CD, et al. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010;90(1):207-58
   PubMed Web of Science ®Google Scholar
• WANG X, Martindale J, LIU Y, Holbrook N. The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J 1998;333:291-300
   PubMed Web of Science ®Google Scholar
• Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2003;35(7):851:9
   Google Scholar
• Sugden PH, Bogoyevitch MA. Intracellular signalling through protein kinases in the heart. Cardiovascular Res 1995;30(4):478-92
   Google Scholar
• Lou H, Kaur K, Sharma AK, Singal PK. Adriamycin-induced oxidative stress, activation of MAP kinases and apoptosis in isolated cardiomyocytes. Pathophysiol 2006;13(2):103-9
   Google Scholar
• Tokudome T, Mizushige K, Noma T, et al. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 2000;36(3):361-8
   PubMed Web of Science ®Google Scholar
• Sacco G, Bigioni M, Evangelista S, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Europ J Pharmacol 2001;414(1):71-8
   PubMedGoogle Scholar
• Hiona A, Lee AS, Nagendran J, et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg 2011;142(2):396-403; e3
   PubMedGoogle Scholar
• Boucek Jr RJ, Steele A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol 2003;3(4):319-29
   Google Scholar
• Richard C, Lauzier B, Delemasure S, et al. Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats. J Cardiovasc Pharmacol 2008;52(3):278-85
   Google Scholar
• Monti M, Terzuoli E, Ziche M, Morbidelli L. The sulphydryl containing ACE inhibitor Zofenoprilat protects coronary endothelium from Doxorubicin-induced apoptosis. Pharmacol Res 2013;76:171-81
   Google Scholar
• Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin treated lymphoma patients: A prospective, parallel group, randomized, controlled study with 36 month follow up. Am J Hematol 2010;85(11):894-6
   Google Scholar
• Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61(23):2355-62
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy–induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114(23):2474-81
   PubMed Web of Science ®Google Scholar
• Radulescu D, Buzdugan E, Ciuleanu T, et al. Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors? J BUON 2013;18(4):1052
   Google Scholar
• Munoz J, Sheqwara J, Arango B, et al. editors. The role of beta-blockers and ACE inhibitors in the prevention of trastuzumab-related cardiotoxicity. ASCO Annual Meeting Proceedings; 2010
   Google Scholar
• Blaes AH, Gaillard P, Peterson BA, et al. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res Treat 2010;122(2):585-90
   Google Scholar
• Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 2013;49(13):2900-9
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10(1):337
   PubMed Web of Science ®Google Scholar
• Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102(1):14-25
   PubMedGoogle Scholar
• Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26(8):1231-8
   PubMed Web of Science ®Google Scholar
• Romond EH, Jeong J-H, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 2012;30(31):3792-9
   PubMed Web of Science ®Google Scholar
• Seicean S, Seicean A, Alan N, et al. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy follow-up study of heart failure. Circ Heart Fail 2013;6(3):420-6
   Google Scholar
• Prevention of Anthracycline-induced Cardiotoxicity (ICOS-ONE). Available from: https://clinicaltrials.gov/ct2/show/NCT01968200
   Google Scholar
• Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research (MANTICORE). Available from: https://clinicaltrials.gov/ct2/show/NCT01016886
   Google Scholar
• Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab. Available from: https://clinicaltrials.gov/ct2/show/NCT01009918
   Google Scholar